---
title: "Glenmark, Cosmo Pharmaceuticals Get UK Regulator's Nod to Market Acne Treatment Winlevi in UK"
date: "2025-02-10 15:46:16"
summary: "Glenmark Pharmaceuticals and Cosmo Pharmaceuticals received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the British country, according to a Monday filing to the Indian stock exchanges. Winlevi is a topical treatment for acne vulgaris. Glenmark has in-licensed the product from Cosmo Pharmaceuticals..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the British country, according to a Monday filing to the Indian stock exchanges.

Winlevi is a topical treatment for acne vulgaris.

Glenmark has in-licensed the product from Cosmo Pharmaceuticals for distribution in Europe and South Africa under a deal signed in September 2023.

Shares of the company were down 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465572:0/)
